AAV vector based generic gene therapy drug for coronavirus infection and preparation method thereof
The invention relates to an AAV vector based generic gene therapy drug for coronavirus infection. The therapy drug includes adeno-associated viruses; the adeno-associated viruses include AAV capsid, ssAAV genomes packed in the AAV capsid, promoters and sequences suitable for coding soluble extracellular region ACE2; and the sequence-encoded protein can be secreted out of cells and has a functionaldomain specifically binding to S protein. The gene sequence encoded with the soluble extracellular region ACE2 protein is introduced into target cells by using the AAV vector, so that the target cells can secret the soluble ACE2 to the outside of the cells so as to bind to the S protein of coronavirus, and therefore, the purpose of antagonizing SARS-CoV infection can be achieved. The gene sequence is the gene fragments encoding the soluble extracellular region ACE2 (1-740) and (1-620) non-full-length protein obtained through deletion based on the gene sequence encoding ACE2 full length protein (1-805), and both the two non-full-length protein reserve the function domain specifically binding to the S protein, can be secreted out of the cells and used for inhibiting the infection of the novel coronavirus..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Europäisches Patentamt - (2020) vom: 29. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DONG WENJI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2020-12-29, Last update posted on www.tib.eu: 2022-09-20, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN112138152 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011481978 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011481978 | ||
| 003 | DE-627 | ||
| 005 | 20230504090811.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210601s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA011481978 | ||
| 035 | |a (EPA)CN112138152 | ||
| 035 | |a (EPA)73893304 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a DONG WENJI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a AAV vector based generic gene therapy drug for coronavirus infection and preparation method thereof |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2020-12-29, Last update posted on www.tib.eu: 2022-09-20, Last updated: 2023-02-09 | ||
| 520 | |a The invention relates to an AAV vector based generic gene therapy drug for coronavirus infection. The therapy drug includes adeno-associated viruses; the adeno-associated viruses include AAV capsid, ssAAV genomes packed in the AAV capsid, promoters and sequences suitable for coding soluble extracellular region ACE2; and the sequence-encoded protein can be secreted out of cells and has a functionaldomain specifically binding to S protein. The gene sequence encoded with the soluble extracellular region ACE2 protein is introduced into target cells by using the AAV vector, so that the target cells can secret the soluble ACE2 to the outside of the cells so as to bind to the S protein of coronavirus, and therefore, the purpose of antagonizing SARS-CoV infection can be achieved. The gene sequence is the gene fragments encoding the soluble extracellular region ACE2 (1-740) and (1-620) non-full-length protein obtained through deletion based on the gene sequence encoding ACE2 full length protein (1-805), and both the two non-full-length protein reserve the function domain specifically binding to the S protein, can be secreted out of the cells and used for inhibiting the infection of the novel coronavirus. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG YANJUN |4 aut | |
| 700 | 0 | |a CAO FAN |4 aut | |
| 700 | 0 | |a ZHAO ZHONGLIANG |4 aut | |
| 700 | 0 | |a LIU ZIJIN |4 aut | |
| 700 | 0 | |a CHENG MOBIN |4 aut | |
| 700 | 0 | |a LI CHANGFENG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2020) vom: 29. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/73893304/publication/CN112138152A1?q=CN112138152 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2020 |b 29 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2020 |b 29 |c 12 | ||